REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (NCT05973773)
Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Who can join: Review the eligibility criteria below.
Location: Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (130 Sites)
Showing the first 25 of 130 sites.
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Southwest — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Northwest — Las Vegas, Nevada
- Gabrail Cancer and Research Center — Canton, Ohio
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven, Flemish Brabant
- Algemeen Ziekenhuis Maria Middelares — Ghent, Oost-Vlaaderen
- Algemeen Ziekenhuis Delta - Campus Menen — Menen, West Flanders
- Algemeen Ziekenhuis Delta - Campus Rumbeke — Rosières, West-Vlaanderen
- Centro Regional Integrado de Oncologia — Fortaleza, Ceará
- Hospital Mãe de Deus - Centro Integrado de Oncologia — Porto Alegre, Rio Grande do Sul
- Hospital São Lucas da PUCRS — Porto Alegre, Rio Grande do Sul
- Clínica Neoplasias Litoral — Itajaí, Santa Catatina
- Hospital Amaral Carvalho — Jaú, São Paulo
- Multi-profile Hospital for Active Treatment Uni Hospital — Panagyurishte, Pazardzhik
- University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL — Sofia, Sofia
- BC Cancer Vancouver — Vancouver, British Columbia
- William Osler Health System - Brampton Civic Hospital — Brampton, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- CentroEstudiosClinicosSAGA — Santiago, Region de Santiago
- Hospital Clínico Universidad de Chile — Independencia, Santiago Metropolitan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.